Submission of the manuscript is online via e-mail or

Tel: +7 903 250 5288

Editorial Correspondence e-mail

Publishing, Subscriptions, Sales and Advertising, Correspondence e-mail

Tel: +7 917 561 9505

SCImago Journal & Country Rank

    1. Federal Almazov North-West Medical Research Centre (St. Petersburg, Russian Federation)

    Keywords:Obesity,Bariatric surgery,Intragastric balloon,Diabetes Mellitus,Remission of type 2 diabetes,BMI

    Abstract:Aims: Obesity is one of the most pressing problems of modern medicine, being not only an independent cause of increasing disability and mortality, but also the basis for the development of the metabolic syndrome with its many manifestations and type 2 diabetes. Meanwhile, attempts to reduce weight with low-caloric diets, pharmacotherapy and lifestyle changes have limited effectiveness and rarely give a lasting result. Minimally invasive methods, such as intragastric baloon, are effective only in some patients, and large surgical interventions are highly effective in most obese patients, but require lifelong limitations and medical supervision. Thus, in order to create an effective algorithm for choosing the treatment of the metabolic syndrome, it is required to identify the predictors of the response to each of the indicated treatment methods, which is the goal of this work. Materials and methods: Study and analysis of literature on studies of foreign authors. Results: as predictors of weight loss during the intragastric balloon treatment can be considered female gender, lower levels of initial BMI, no compulsive overeating (“binge eating”); for large surgical interventions - BMI, C-peptide level and duration of type 2 diabetes. Conclusions: Summarizing the results of numerous studies, the predictors with good evidence base in reducing body weight of patients with diabetes include BMI, and gender. Well studied factors of glycemia compensation during treatment are the preservation function of beta cells, which effectively confirms the level of C-peptide and concomitant glucose-lowering therapy. The age characteristics, the level orexigenic and anorectic hormones, psycho-social characteristics of patients, the initial compensation level of glycemia require further study.

      1. CDC. National Diabetes Statistics Report, 2014. Available at: Last accessed September 2015.
      2. Calvera MA, de Aldrade M, Mesas AE, et al. W. J. Obes. 2015 Feb; 31 (2): 244-253 Is Obesity Predictive of Cardivascular disfunction independent of Cardiovascular Risk Factors?
      3. Williamson, DE. Descriptive epidemioiogy of body weight and body weight change in U.S. adults. Annals of lnternal Medicine, 1993; 119: 646-649.
      4. Laville M, Andreelli F. Mechanisms for weight gain during blood glucose normalization. Diabetes&Metabolism. 2000; 26(3): 42-5.
      5. Gregg EW, Chen H, Wagenknecht LE, Clark JM, Delahanty LM, Bantle J et al. Association of an intensive. lifestyle intervention with remission of type 2 diabetes. Journal of the American Medical Association. 2012;308(23):2489-96. doi: 10.1001/jama.2012.67929.
      6. Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. Journal of the American Medical Association. 2014;311(1):74-86. doi: 10.1001/jama.2013.281361.
      7. Hermansen K, Mortensen LS. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Safety 2007;30(12):1127-1142.
      8. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352(9131):837-53.
      9. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. Journal of the American Medical Association. 2002;287(3):360-372. doi:10.1001/jama.287.3.360.
      10. Ramhamadany EM, Fowler J, Baird IM. Effect of the gastric balloon versus sham procedure on weight loss in obese subjects. Gut. 1989;30(8):1054-7.
      11. Gómez V, Woodman G, Abu Dayyeh BK. Delayed gastric emptying as a proposed mechanism of action during intragastric balloon therapy: Results of a prospective study. Obesity (Silver Spring). 2016;24(9):1849-53. doi: 10.1002/oby.21555.
      12. Genco A, Roberta M, Massimiliano C, Emanuele S, Giovanni C, Adriano R. Endoscopic treatment: intragastric balloon. In: Lucchese M & Scopinaro N (Eds.). Minimally invasive bariatric and metabolic surgery. Springer International Publishing; 2015. p. 145-152.
      13. Imaz I, Martínez-Cervell C, García-Alvarez EE, Sendra-Gutiérrez JM, González-Enríquez J. Safety and effectiveness of the intragastric balloon for obesity. A meta-analysis. Obesity Surgery. 2008; 18(7):841-6. doi: 10.1007/s11695-007-9331-8.
      14. Mazure RA, Salgado G, Villarreal P, Cobo B, Valencia A, Culebras JM. Intragastric balloon and multidisciplinary team. Nutricion Hospitalaria. 2009;24(3):282-7.
      15. Kotzampassi K, Grosomanidis V, Papakostas P, Penna S, Eleftheriadis E. 500 intragastric balloons: what happens 5 years thereafter? Obesity Surgery. 2012;22(6):896-903. doi: 10.1007/s11695-012-0607-2.
      16. Forlano R, Ippolito AM, Iacobellis A, Merla A, Valvano MR, Niro G et al. Effect of the BioEnterics intragastric balloon on weight, insulin resistance, and liver steatosis in obese patients. Gastrointestinal Endoscopy. 2010;71(6):927-33. doi: 10.1016/j.gie.2009.06.036.
      17. Mui WL, Ng EK, Tsung BY, Lam CH, Yung MY. Impact on obesity-related illnesses and quality of life following intragastric balloon. Obesity Surgery. 2010;20:1128-1132. doi: 10.1007/s11695-008-9766-6.
      18. Genco A, López-Nava G, Wahlen C, Maselli R, Cipriano M, Sanchez MM et al. Multi-centre European experience with intragastric balloon in overweight populations: 13 years of experience. Obesity Surgery. 2013;23(4):515-21. doi: 10.1007/s11695-012-0829-3.
      19. Mitura K, Garnysz K. In search of the ideal patient for the intragastric balloon - short- and long-term results in 70 obese patients. Videosurgery and Other Miniinvasive Techniques. 2016;10(4):541-7. doi: 10.5114/wiitm.2015.55748.
      20. Kotzampassi K, Shrewsbury AD, Papakostas P, Penna S, Tsaousi GG, Grosomanidis V. Looking into the profile of those who succeed in losing weight with an intragastric balloon. Journal of laparoendoscopic & advanced surgical techniques. Part A. 2014;24(5):295-301. doi: 10.1089/lap.2013.0439.
      21. Martinis Fernandes FA Jr, Carvalho GL, Lima DL, Rao P, Shadduck PP, Montandon ID et al. Intragastric Balloon for Overweight Patients. Journal of the Society of Laparoendoscopic Surgeons.2016; 20(1). pii: e2015.00107. doi: 10.4293/JSLS.2015.00107.
      22. Tai CM, Lin HY, Yen YC, Huang CK, Hsu WL, Huang YW et al. Effectiveness of intragastric balloon treatment for obese patients: one-year follow-up after balloon removal. Obesity Surgery. 2013;23(12):2068-74. doi: 10.1007/s11695-013-1027-7.
      23. Madeira E, Madeira M, Guedes EP, Mafort TT, Neto LV, de Oliveira Moreira R et al. Assessment of predictive response factors to intragastric balloon therapy for the treatment of obesity. Journal of laparoendoscopic & advanced surgical techniques. Part A. 2016;26(3):168-73. doi: 10.1089/lap.2015.0305.
      24. Dogan UB, Gumurdulu Y, Akin MS, Yalaki S. Five percent weight lost in the first month of intragastric balloon treat-ment may be a predictor for long-term weight aintenance. Obesity Surgery. 2013;23(7):892-6. doi: 10.1007/s11695-013-0876-4.
      25. Ihiiya T, Nakazato M, Mizuta M et al. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 2002; 87: 240-244.
      26. Mion F, Napoléon B, Roman S, Malvoisin E, Trepo F, Pujol B et al. Effects of intragastric balloon on gastric emptying and plasma ghrelin levels in non-morbid obese patients. Obesity Surgery. 2005;15(4):510-516. doi: 10.1381/0960892053723411
      27. Martinez-Brocca MA, Belda O, Parejo J, Jimenez L, del Valle A, Pereira JL et al. Intragastric balloon-induced satiety is not mediated by modification in fasting or postprandial plasma ghrelin levels in morbid obesity. Obesity Surgery. 2007;17(5):649-57.
      28. Nikolic M, Boban M, Ljubicic N, Supanc V, Mirosevic G, Pezo Nikolic B et al. Morbidly obese are ghrelin and leptin hyporesponders with lesser intragastric balloon treatment efficiency: ghrelin and leptin changes in relation to obesity treatment. Obesity Surgery. 2011;21(10):1597-604. doi: 10.1007/s11695-011-0414-1.
      29. Fuller NR, Lau NS, Denyer G, Caterson ID. An intragastric balloon produces large weight losses in the absence of a change in ghrelin or peptide YY. Clinical Obesity. 2013;3(6):172-9. doi: 10.1111/cob.12030.
      30. Bužga M, Evžen M, Pavel K, Tomáš K, Vladislava Z, Pavel Z et al. Effects of the intragastric balloon MedSil on weight loss, fat tissue, lipid metabolism, and hormones involved in energy balance. Obesity Surgery. 2014;24(6):909-15. doi: 10.1007/s11695-014-1191-4.
      31. Mathus-Vliegen EM, Eichenberger RI. Fasting and meal-suppressed ghrelin levels before and after intragastric balloons and balloon-induced weight loss. Obesity Surgery. 2014;24(1):85-94. doi: 10.1007/s11695-013-1053-5.
      32. Konopko-Zubrzycka M, Baniukiewicz A, Wróblewski E, Kowalska I, Zarzycki W, Górska M et al. The effect of intragastric balloon on ghrelin, leptin and adiponectin levels in patients with morbid obesity. Journal Of Clinical Endocrinology And Metabolism. 2009;94(5):1644-9. doi: 10.1210/jc.2008-1083.
      33. Crujeiras AB, Goyenechea E, Abete I, Lage M, Carreira MC, Martínez JA et al. Weight regain after a diet-induced loss is predicted by higher baseline leptin and lower ghrelin plasma levels. Journal Of Clinical Endocrinology And Metabolism. 2010;95(11):5037-44. doi: 10.1210/jc.2009-2566.
      34. Williams DL, Baskin DG, Schwartz MW. Leptin regulation of the anorexic response to glucagon-like peptide-1 receptor stimulation. Diabetes. 2006;55(12):3387-93. doi: 10.2337/db06-0558.
      35. Bacha F, Saad R, Gungor N, Arslanian SA. Adiponectin in youth, relationship to visceral adiposity, insulin sensitivity, and beta-cell function. Diabetes Care. 2004;27(2):547-52.
      36. Fu Y, Luo N, Klein RL, Garvey WT. Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation. Journal of Lipid Research. 2005;46(7):1369-79. doi: 10.1194/jlr.M400373-JLR 200.
      37. Mathus-Vliegen EM, de Groot GH. Fasting and meal-induced CCK and PP secretion following intragastric balloon treatment for obesity. Obesity Surgery. 2013;23(5):622-33. doi: 10.1007/s11695-012-0834-6.
      38. Fuller NR, Lau NS, Denyer G, Caterson ID. An intragastric balloon produces large weight losses in the absence of a change in ghrelin or peptide YY. Clinical Obesity. 2013;3(6):172-9. doi: 10.1111/cob.12030
      39. Cugini P, Cilli M, Salandri A, Ceccotti P, Di MA, Rodio A et al. Anxiety, depression, hunger and body composition: III. Their relationships in obese patients. Eating And Weight Disorders. 1999;4(3):115-20.
      40. Hillman JB, Dorn LD, Huang B. Association of anxiety and depressive symptoms and adiposity among adolescent females using dual energy X-ray absorptiometry. Clinical Pediatrics (Phila). 2010;49:671-7.
      41. Guedes EP, Madeira E, Mafort TT, Madeira M, Moreira RO, Mendonça MC et al. Body composition and depressive/anxiety symptoms in overweight and obese individuals with metabolic syndrome. Diabetology & Metabolic Syndrome. 2013. 5(1):82. doi: 10.1186/1758-5996-5-82.
      42. Puglisi F, Antonucci N, Capuano P, Zavoianni L, Lobascio P, Martines G et al. Intragastric balloon and binge eating. Obesity Surgery. 2007;17(4):504-9. doi: 10.1007/s11695-007-9088-0.
      43. Dumonceau JM. Evidence-based review of the Bioenterics intragastric balloon for weight loss. Obesity Surgery. 2008;18(12):1611-7. doi: 10.1007/s11695-008-9593-9.
      44. Deliopoulou K, Konsta A, Penna S, Papakostas P, Kotzampassi K. The impact of weight loss on depression status in obese individuals subjected to intragastric balloon treatment. Obesity Surgery. 2013;23(5):669-75. doi: 10.1007/s11695-012-0855-1.
      45. Мельникова Е. В., Бабенко А. Ю., Неймарк А. Е. Влияние нарушения пищевого поведения на компенсацию гликемии и снижение массы тела при разных подходах к терапии// Конгресс «Эндокринология Северо-запада России 2015» 18-20 июня 2015 г., Санкт-Петербург - тезисы докладов: с. 37.
      46. Bhasker A. G. et al. Predictors of Remission of T2DM and Metabolic Effects after Laparoscopic Roux-en-y Gastric Bypass in Obese Indian Diabetics - a 5-Year Study // Obes. Surg. 2014.
      47. Chattranukulchai Shantavasinkul P. et al. Predictors of weight regain in patients who underwent Roux-en-Y gastric bypass surgery // 2016.
      48. Lars Sjöström et al. Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric Surgery // N. Engl. J. Med. 2004. С. 2683-2693.
      49. Wood G. C. et al. Association of DiaRem Score With Cure of Type 2 Diabetes Following Bariatric Surgery // JAMA Surg. 2016. Т. 151. № 8. С. 779.
      50. Brandenburg D. History and diagnostic significance of C-peptide.Exp Diabetes Res 2008: 576862
      51. Schauer PR, Burguera B, Ikramuddin S, Cottam D, Gourash W, Hama G, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg. 2003; 238:467-84. discussion 84-5.
      52. Aarts, E. O., Janssen, J., Janssen, I. M. C., Berends, F. J., Telting, D., & De Boer, H. (2013). Preoperative fasting plasma C-peptide level may help to predict diabetes outcome after gastric bypass surgery. Obesity Surgery, 23(7), 867-873.

    Full text is published :
    Tihonenko E.V., Babenko A.Yu., Neimark A.E., Korniushin S.V., Boyarskaya I.A. PREDICTORS OF WEIGHT LOSS AND REMISSION OF DIABETES AFTER THE INTRAGASTRIC BALLOON TREATMENT AND OTHER BARIATRIC PROCEDURES. Experimental and Clinical Gastroenterology Journal. 2017;143(07):82-88
    Read & Download full text